| Matthew Royal Wilson, CRNA | |
|
36475 Five Mile Rd, Livonia, MI 48154-1971 | |
| (734) 655-4800 | |
| Not Available |
| Full Name | Matthew Royal Wilson |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 5 Years |
| Location | 36475 Five Mile Rd, Livonia, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356988547 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 4704299657 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joe Mercy Hospital System Livonia | Livonia, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rochester Medical Associates Pllc | 8729318704 | 30 |
| St Mary Mercy Hospital Crna | 8820163538 | 48 |
News Archive
As the search for effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, a new study published on the preprint bioRxiv in November 2020 discusses the role of synthetic nanobodies or sybodies in neutralizing the virus by binding to its receptor-binding domain (RBD) on the spike protein.
Global Solutions for Infectious Diseases ("GSID") announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The double-blind, placebo controlled study was conducted in Thailand among more than 16,000 volunteers.
Valeant today announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International, Inc.
Using practical nano-DDS technology, a polymeric nanomicelle that effectively delivers the potent mitotic inhibitor desacetyl vinblastine hydrazide (DAVBNH) to glioblastoma (GBM) was developed.
A research team may have broken the stubborn impasse that has frustrated the invention of an effective HIV vaccine, by using an approach that bypasses the usual path followed by vaccine developers.
› Verified 9 days ago
| Entity Name | St Mary Mercy Hospital Crna |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063602092 PECOS PAC ID: 8820163538 Enrollment ID: O20080814000520 |
News Archive
As the search for effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, a new study published on the preprint bioRxiv in November 2020 discusses the role of synthetic nanobodies or sybodies in neutralizing the virus by binding to its receptor-binding domain (RBD) on the spike protein.
Global Solutions for Infectious Diseases ("GSID") announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The double-blind, placebo controlled study was conducted in Thailand among more than 16,000 volunteers.
Valeant today announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International, Inc.
Using practical nano-DDS technology, a polymeric nanomicelle that effectively delivers the potent mitotic inhibitor desacetyl vinblastine hydrazide (DAVBNH) to glioblastoma (GBM) was developed.
A research team may have broken the stubborn impasse that has frustrated the invention of an effective HIV vaccine, by using an approach that bypasses the usual path followed by vaccine developers.
› Verified 9 days ago
| Entity Name | Asa Staffing Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114378981 PECOS PAC ID: 3971898644 Enrollment ID: O20160818002713 |
News Archive
As the search for effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, a new study published on the preprint bioRxiv in November 2020 discusses the role of synthetic nanobodies or sybodies in neutralizing the virus by binding to its receptor-binding domain (RBD) on the spike protein.
Global Solutions for Infectious Diseases ("GSID") announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The double-blind, placebo controlled study was conducted in Thailand among more than 16,000 volunteers.
Valeant today announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International, Inc.
Using practical nano-DDS technology, a polymeric nanomicelle that effectively delivers the potent mitotic inhibitor desacetyl vinblastine hydrazide (DAVBNH) to glioblastoma (GBM) was developed.
A research team may have broken the stubborn impasse that has frustrated the invention of an effective HIV vaccine, by using an approach that bypasses the usual path followed by vaccine developers.
› Verified 9 days ago
| Entity Name | Rochester Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396398681 PECOS PAC ID: 8729318704 Enrollment ID: O20190918002717 |
News Archive
As the search for effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, a new study published on the preprint bioRxiv in November 2020 discusses the role of synthetic nanobodies or sybodies in neutralizing the virus by binding to its receptor-binding domain (RBD) on the spike protein.
Global Solutions for Infectious Diseases ("GSID") announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The double-blind, placebo controlled study was conducted in Thailand among more than 16,000 volunteers.
Valeant today announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International, Inc.
Using practical nano-DDS technology, a polymeric nanomicelle that effectively delivers the potent mitotic inhibitor desacetyl vinblastine hydrazide (DAVBNH) to glioblastoma (GBM) was developed.
A research team may have broken the stubborn impasse that has frustrated the invention of an effective HIV vaccine, by using an approach that bypasses the usual path followed by vaccine developers.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Royal Wilson, CRNA 555 Kingsley Trl, Bloomfield Hills, MI 48304-2317 Ph: (248) 736-2037 | Matthew Royal Wilson, CRNA 36475 Five Mile Rd, Livonia, MI 48154-1971 Ph: (734) 655-4800 |
News Archive
As the search for effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, a new study published on the preprint bioRxiv in November 2020 discusses the role of synthetic nanobodies or sybodies in neutralizing the virus by binding to its receptor-binding domain (RBD) on the spike protein.
Global Solutions for Infectious Diseases ("GSID") announced today that a Phase III clinical trial of an investigational HIV vaccine regimen has been shown to be safe and modestly effective in preventing HIV infection. The double-blind, placebo controlled study was conducted in Thailand among more than 16,000 volunteers.
Valeant today announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International, Inc.
Using practical nano-DDS technology, a polymeric nanomicelle that effectively delivers the potent mitotic inhibitor desacetyl vinblastine hydrazide (DAVBNH) to glioblastoma (GBM) was developed.
A research team may have broken the stubborn impasse that has frustrated the invention of an effective HIV vaccine, by using an approach that bypasses the usual path followed by vaccine developers.
› Verified 9 days ago
Ashley Staubin, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 36475 Five Mile Rd, Livonia, MI 48154 Phone: 734-655-4800 | |
Avis J Dorsey, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 12031 Cardwell St, Livonia, MI 48150 Phone: 248-982-7385 | |
Misty Tyburski, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 36475 Five Mile Rd, Livonia, MI 48154 Phone: 734-655-4800 | |
Sheri Sparkman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 36475 5 Mile Rd, Livonia, MI 48154 Phone: 734-655-2022 | |
Sarah Krater, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 36475 Five Mile Rd, Livonia, MI 48154 Phone: 734-655-4800 | |
Andrea Kline Ozimek, CRNA, MS Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 36475 Five Mile Rd, Livonia, MI 48154 Phone: 734-655-2031 | |
Kathleen Collins, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 36475 5 Mile Rd, Livonia, MI 48154 Phone: 734-655-2022 |